A360
Key Takeaways✦ Atlas AI
01
Elevated lipoprotein(a) (Lp(a)) significantly increases the risk of stroke and cardiovascular death, especially in those with existing heart disease, highlighting its role beyond traditional risk factors.
02
Lp(a) levels, being genetically determined and unaffected by lifestyle, represent a persistent, unaddressed cardiovascular risk for approximately 20% of the population.
03
The identified risk threshold of 175 nmol/L for Lp(a) could revolutionize cardiovascular risk assessment and lead to more targeted, aggressive management strategies for high-risk individuals.
Atlas AI
A new analysis suggests that very high levels of lipoprotein(a), or Lp(a), are associated with a higher risk of major cardiovascular events—particularly stroke and cardiovascular death—especially among people who already have cardiovascular disease.
The study did not find a clear association between elevated Lp(a) and heart attack risk in this analysis. Researchers say the results support Lp(a) as an important genetic risk factor that may help refine cardiovascular risk assessment, particularly when risk remains elevated despite standard treatment.
What the analysis found
According to the report, people with Lp(a) levels of 175 nmol/L or higher had a significantly higher risk of stroke and cardiovascular death. The association was strongest among individuals with pre-existing cardiovascular disease, pointing to Lp(a) as a potential contributor to “residual” risk—ongoing risk even when other factors, such as LDL cholesterol, are being treated.
Why Lp(a) is often overlooked
Lp(a) is a cholesterol-carrying particle in the blood that is largely determined by genetics and is not significantly influenced by diet or exercise. Despite estimates that roughly 20% of people have elevated Lp(a), testing is not routinely performed.
The analysis highlighted 175 nmol/L as a threshold linked to substantially increased risk. Researchers suggest that identifying patients with very high Lp(a) could support more aggressive management of other cardiovascular risk factors and inform future treatment strategies.
